Zobrazeno 1 - 10
of 190
pro vyhledávání: '"Tsutomu Mizoshita"'
Autor:
Taketo Suzuki, Tsutomu Mizoshita, Satoshi Tanida, Naomi Sugimura, Takahito Katano, Hirotada Nishie, Hiromi Kataoka
Publikováno v:
JGH Open, Vol 3, Iss 3, Pp 217-223 (2019)
Background and Aim Tacrolimus (TAC) is an important therapeutic option for remission induction in patients with refractory ulcerative colitis (UC). However, there is little evidence available on long‐term outcomes and maintenance treatments after T
Externí odkaz:
https://doaj.org/article/9f613da257ad4589b85f16269608c38c
Urinary Cysteine-Rich Protein 61 and Trefoil Factor 3 as Diagnostic Biomarkers for Colorectal Cancer
Autor:
Takaya Shimura, Hiroyasu Iwasaki, Mika Kitagawa, Masahide Ebi, Tamaki Yamada, Tomonori Yamada, Takahito Katano, Hirotada Nisie, Yasuyuki Okamoto, Keiji Ozeki, Tsutomu Mizoshita, Hiromi Kataoka
Publikováno v:
Translational Oncology, Vol 12, Iss 3, Pp 539-544 (2019)
Since a fecal occult blood test for colorectal cancer (CRC) does not offer sufficient diagnostic power for CRC, novel non-invasive biomarkers are hopeful for CRC screening. We conducted the current study to discover non-invasive urinary biomarkers fo
Externí odkaz:
https://doaj.org/article/e2ccc21c88624e17ae2bbe6a7601c19c
Autor:
Taketo Suzuki, Tsutomu Mizoshita, Tomoya Sugiyama, Yoshikazu Hirata, Yoshihide Kimura, Yuka Suzuki, Tomonori Yamada, Hironobu Tsukamoto, Takashi Mizushima, Naomi Sugimura, Takahito Katano, Satoshi Tanida, Hiromi Kataoka, Makoto Sasaki
Publikováno v:
Case Reports in Gastroenterology, Vol 13, Iss 1, Pp 37-49 (2019)
Background/Aims: Adalimumab dose escalation is one of the most important options in refractory Crohn’s disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in C
Externí odkaz:
https://doaj.org/article/003724b9516e4742b67eccd609200e7a
Autor:
Tsutomu Mizoshita, Satoshi Tanida, Keiji Ozeki, Takahito Katano, Takaya Shimura, Yoshinori Mori, Eiji Kubota, Hiromi Kataoka, Takeshi Kamiya, Takashi Joh
Publikováno v:
Case Reports in Gastroenterology, Vol 10, Iss 2, Pp 283-291 (2016)
There is little evidence regarding the maintenance of long-term clinical remission by adalimumab (ADA) therapy in Crohn’s disease (CD) patients naïve to anti-tumor necrosis factor treatment (naïve CD patients), since most CD patients are treated
Externí odkaz:
https://doaj.org/article/fae603fa085844d08f2f56af19996cc9
Autor:
Keiji Ozeki, Satoshi Tanida, Tsutomu Mizoshita, Hironobu Tsukamoto, Masahide Ebi, Yoshinori Mori, Hiromi Kataoka, Takeshi Kamiya, Takashi Joh
Publikováno v:
Case Reports in Gastroenterology, Vol 6, Iss 3, Pp 765-771 (2012)
Adalimumab (ADA) is applied to induce remission in patients with Crohn’s disease (CD) naïve to chimeric anti-tumor necrosis factor-α (anti-TNF-α), infliximab or patients with loss of response to scheduled maintenance infliximab. Adsorptive granu
Externí odkaz:
https://doaj.org/article/754ab37974af4768a32ee66891586047
Autor:
Satoshi Tanida, Masaya Takemura, Tsutomu Mizoshita, Keiji Ozeki, Takahito Katano, Takaya Shimura, Yoshinori Mori, Eiji Kubota, Hiromi Kataoka, Takeshi Kamiya, Takashi Joh
Publikováno v:
Case Reports in Gastrointestinal Medicine, Vol 2016 (2016)
A 64-year-old man with Crohn’s disease (CD) was admitted to our hospital due to moderate risk of pneumonia while receiving scheduled adalimumab maintenance therapy. Symptoms remained virtually unchanged following administration of antibiotics. A fi
Externí odkaz:
https://doaj.org/article/753e88b081f64b4ca90c31067b66ee9e
Autor:
Takashi Mizushima, Satoshi Tanida, Tsutomu Mizoshita, Yoshikazu Hirata, Kenji Murakami, Takaya Shimura, Hiromi Kataoka, Takeshi Kamiya, Takashi Joh
Publikováno v:
Case Reports in Gastroenterology, Vol 5, Iss 1, Pp 144-151 (2011)
A 36-year-old woman who had been diagnosed with ulcerative colitis at the age of 17 years was referred to our hospital because of severe abdominal pain and repeated bloody diarrhea that persisted during pregnancy despite combination therapy with high
Externí odkaz:
https://doaj.org/article/cfaf6e1903634579898fbcafe730cae5
Autor:
Tsutomu Mizoshita, Satoshi Tanida, Hironobu Tsukamoto, Keiji Ozeki, Takahito Katano, Hirotaka Nishiwaki, Masahide Ebi, Yoshinori Mori, Eiji Kubota, Hiromi Kataoka, Takeshi Kamiya, Takashi Joh
Publikováno v:
Gastroenterology Research and Practice, Vol 2014 (2014)
Background. Adalimumab (ADA) is effective for patients with Crohn’s disease (CD). However, there have been few reports on ADA therapy with respect to its relationship with pathologic findings and drug efficacy in biologically naïve CD cases. Metho
Externí odkaz:
https://doaj.org/article/431717d2363149bb9ba11fd4ac89dc4c
Autor:
Keiji Ozeki, Satoshi Tanida, Chie Morimoto, Yoshimasa Inoue, Tsutomu Mizoshita, Hironobu Tsukamoto, Takaya Shimura, Hiromi Kataoka, Takeshi Kamiya, Eiji Nishiwaki, Hiroshi Ishiguro, Shigeki Higashiyama, Takashi Joh
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e56770 (2013)
BACKGROUND AIMS: Current treatment target toward advanced colorectal cancers is mainly focused on the epidermal growth factor receptor (EGFR) signaling, but its additive effects with chemotherapy are still limited. A disintegrin and metalloproteinase
Externí odkaz:
https://doaj.org/article/ba2a0cad1d9b4d3587c2fc7c2d83e23a
Autor:
Satoshi Tanida, Tsutomu Mizoshita, Keiji Ozeki, Hironobu Tsukamoto, Takeshi Kamiya, Hiromi Kataoka, Daitoku Sakamuro, Takashi Joh
Publikováno v:
International Journal of Surgical Oncology, Vol 2012 (2012)
Cisplatin is the most important and efficacious chemotherapeutic agent for the treatment of advanced gastric cancer. Cisplatin forms inter- and intrastrand crosslinked DNA adducts and its cytotoxicity is mediated by propagation of DNA damage recognit
Externí odkaz:
https://doaj.org/article/9a3521fdc6704a4dac97196bb4d42685